Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
- Editas Medicine assumed with a Neutral at Credit Suisse
- Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
- Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
- Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update